Principles for Patient-Centered Prescription Drug Coverage

Read Forum Report here.

Principles for Patient-Centered Prescription Drug Coverage

Monday, September 11, 2017  
8:30am – 1:30 pm

National Press Club
Holeman Lounge
529 14th St NW
Washington, DC 20045
 
Panel One:     How PBMs Affect Access and Affordability
 
Moderator:      Peter J. Pitts, President, CMPI
Panelists:         B. Douglas Hoey, CEO, National Community Pharmacists Association
                        Nick Ferreyros, Director of Communications, Community Oncology Alliance
                        Derek Daggett, Senior Business Development Executive, SmithRx

Watch Panel One highlights here.

Keynote Speaker: A. Mark Fendrick, M.D., Director, Center for Value Based Insurance Design, University of Michigan
                             Introduction by Robert M. Goldberg, CMPI

Watch Dr. A. Mark Fendrick's Keynote Remarks here.

Panel Two:     Principles for PBM Reform and Patient-Centered Prescription Drug Benefits
 
Moderator:      Robert M. Goldberg, PhD, Vice President, CMPI

Panelists:         Shawn Lovering, President, RxTE
                        Susan Pilch, Vice President, Policy & Regulatory Affairs, National Community Pharmacists Association
                   A. Mark Fendrick, M.D., Director, Center for Value Based Insurance Design, University of Michigan
                       Burt Zweigenhaft, Managing Partner, Upstream Partners
 
Watch Panel Two highlights here.
 
Sign Up for Our Email Newsletter

RECENT NEWS

Health sharing, a viable option for health care

Health sharing, a viable option for health care

One of the key lessons we’ve learned from the Obamacare experience is that “having health insurance” isn’t the same thing...  Read more

Zeroing Out Drug Prices

Zeroing Out Drug Prices

There are some tough but important basic principles when it comes to innovation in health care technologies....  Read more

Elizabeth Warren's Threat to Medical Progress

Elizabeth Warren's Threat to Medical Progress

Senator Elizabeth Warren (D-MA) mistakenly believes that pharmaceutical innovation is primarily driven by the National In...  Read more

DRUGWONKS BLOG